The Medicines and Healthcare products Regulatory Agency (MHRA)  have just announced the approval of Dovonex Psoriasis Ointment to be made available through pharmacies without a prescription.

At talkhealth we would like to thank everyone that responded to our request to volunteer to take part in the public consultation, as from this the Commission on Human Medicines (CHM) advised in favour of the product being available in pharmacies for the treatment of mild to moderate plaque psoriasis which has been previously diagnosed by a doctor in adults aged 18 years and over. The treatment is for application once daily, with maximum duration of use of 12 weeks and maximum pack size of 60g of ointment.

If you are interested to take part in the public consultation process of the reclassification on drugs, please do keep a look out for future requests on talkhealth.  The process is very simple, and entails just taking a short survey on talkhealth to see if you qualify and then you will be invited to the MHRA offices in London to take part in a closed panel discussion normally for half a day.


Add a comment

Your email address will not be published. Required fields are marked *